Relay Therapeutics, founded in Cambridge, United States, is a clinical-stage precision medicines company dedicated to transforming the drug discovery process. Their core mission is to revolutionize the understanding of protein motion and its relation to protein function, utilizing advanced computational power and experimental techniques. Relay Therapeutics offers a unique drug discovery platform, Dynamo™, which aims to effectively target previously intractable or inadequately drugged proteins. Their market focus is on creating new possibilities in drug discovery for various challenging medical conditions.

Notable affiliated individuals include experts in computational biology and drug development, though specific names are not provided. The company has attracted significant investment from leading venture capital firms, underscoring its innovative approach. Key achievements include the development of a robust pipeline of drug candidates and the establishment of a novel platform that enhances the precision and efficacy of drug discovery. Relay Therapeutics' impact lies in its potential to address unmet medical needs by making previously undruggable targets accessible, thereby advancing the field of precision medicine.